View ValuationLibra Infusions 将来の成長Future 基準チェック /06現在、 Libra Infusionsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.New Risk • Sep 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2019 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (৳1.97b market cap, or US$16.4m).Board Change • Apr 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Nov 06Upcoming dividend of ৳3.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 13 November 2023. Payment date: 01 January 2024. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (3.2%). Lower than average of industry peers (2.5%).New Risk • Oct 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2019 fiscal period end). Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risk Market cap is less than US$100m (৳2.54b market cap, or US$23.0m).お知らせ • Oct 24Libra Infusions Limited, Annual General Meeting, Nov 30, 2023Libra Infusions Limited, Annual General Meeting, Nov 30, 2023, at 11:00 Bangladesh Standard Time.Board Change • Nov 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Aug 07Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 14 August 2022. Payment date: 20 September 2022. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.7%). Lower than average of industry peers (1.9%).お知らせ • Jul 25Libra Infusions Limited Recommends Cash DividendThe Board of Directors of Libra Infusions Limited has recommended 5% cash dividend only for General Shareholders other than Sponsors and Directors for the year ended June 30, 2020.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 27Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 04 May 2021. Payment date: 23 June 2021. Trailing yield: 0.4%. Lower than top quartile of Bangladeshi dividend payers (3.5%). Lower than average of industry peers (1.5%).Is New 90 Day High Low • Mar 01New 90-day high: ৳685The company is up 17% from its price of ৳586 on 01 December 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 17% over the same period.Is New 90 Day High Low • Feb 01New 90-day low: ৳582The company is down 11% from its price of ৳657 on 03 November 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 21% over the same period.Is New 90 Day High Low • Dec 21New 90-day high: ৳677The company is up 1.0% from its price of ৳670 on 22 September 2020. The Bangladeshi market is also up 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Libra Infusions は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DSE:LIBRAINFU - アナリストの将来予測と過去の財務データ ( )BDT Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20191972-515N/A6/30/2018191604N/A3/31/2018191-16-76N/A12/31/20172415015N/A9/30/20172455-512N/A6/30/20172446-132N/A3/31/201729052935N/A12/31/201625931619N/A9/30/201623186571N/A6/30/201623866071N/A3/31/20162329267N/A12/31/20152476N/AN/AN/A9/30/2015272-4N/AN/AN/A6/30/20152874-789N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: LIBRAINFUの予測収益成長が 貯蓄率 ( 4.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: LIBRAINFUの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: LIBRAINFUの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: LIBRAINFUの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: LIBRAINFUの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: LIBRAINFUの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:04終値2026/05/21 00:00収益2019/06/30年間収益2019/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Libra Infusions Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
New Risk • Sep 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2019 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (৳1.97b market cap, or US$16.4m).
Board Change • Apr 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Nov 06Upcoming dividend of ৳3.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 13 November 2023. Payment date: 01 January 2024. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (3.2%). Lower than average of industry peers (2.5%).
New Risk • Oct 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2019 fiscal period end). Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risk Market cap is less than US$100m (৳2.54b market cap, or US$23.0m).
お知らせ • Oct 24Libra Infusions Limited, Annual General Meeting, Nov 30, 2023Libra Infusions Limited, Annual General Meeting, Nov 30, 2023, at 11:00 Bangladesh Standard Time.
Board Change • Nov 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Aug 07Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 14 August 2022. Payment date: 20 September 2022. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.7%). Lower than average of industry peers (1.9%).
お知らせ • Jul 25Libra Infusions Limited Recommends Cash DividendThe Board of Directors of Libra Infusions Limited has recommended 5% cash dividend only for General Shareholders other than Sponsors and Directors for the year ended June 30, 2020.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 27Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 04 May 2021. Payment date: 23 June 2021. Trailing yield: 0.4%. Lower than top quartile of Bangladeshi dividend payers (3.5%). Lower than average of industry peers (1.5%).
Is New 90 Day High Low • Mar 01New 90-day high: ৳685The company is up 17% from its price of ৳586 on 01 December 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 17% over the same period.
Is New 90 Day High Low • Feb 01New 90-day low: ৳582The company is down 11% from its price of ৳657 on 03 November 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 21% over the same period.
Is New 90 Day High Low • Dec 21New 90-day high: ৳677The company is up 1.0% from its price of ৳670 on 22 September 2020. The Bangladeshi market is also up 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.